Related Experiment Video
Updated: May 31, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
TFPI2 in tumor metastasis: a double-edged sword with clinical implications
Zhanli Guo1, Yuanke Luo1, Jinyu Wen1
1TCM Prevention and Treatment of Metabolic and Chronic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Abstract:
Tissue factor pathway inhibitor 2 (TFPI2), a serine protease inhibitor, plays a multifaceted role in tumor metastasis. Traditionally viewed as a metastasis suppressor, it inhibits extracellular matrix (ECM) remodeling, epithelial-mesenchymal transition, and angiogenesis. However, emerging evidence indicates that TFPI2 promotes tumor progression in glioblastoma, melanoma, and other cancers by fostering an immunosuppressive tumor microenvironment, mediating pathological ECM remodeling, and enhancing angiogenesis and hematogenous dissemination. Notably, even within the same metastatic cascade, TFPI2 exhibits divergent expression patterns and context-dependent opposing functions, acting either as a metastasis suppressor or promoter. This review summarizes its context-dependent regulatory mechanisms, investigates the underlying basis from structural duality, microenvironmental heterogeneity, and receptor differences, and evaluates its potential as a therapeutic target. Future research should elucidate spatiotemporal microenvironmental dynamics to support early screening and precise intervention.
Insights
Tissue factor pathway inhibitor 2 (TFPI2) has dual roles in cancer metastasis, acting as both a suppressor and promoter. Its function depends on context, highlighting its complexity as a therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Tissue factor pathway inhibitor 2 (TFPI2) is a serine protease inhibitor with known roles in tumor metastasis.
- Traditionally considered a metastasis suppressor, TFPI2 inhibits extracellular matrix remodeling, epithelial-mesenchymal transition, and angiogenesis.
Purpose of the Study:
- To review the context-dependent functions of TFPI2 in cancer metastasis.
- To explore the regulatory mechanisms, structural duality, microenvironmental heterogeneity, and receptor differences underlying TFPI2's opposing roles.
- To evaluate TFPI2 as a potential therapeutic target.
Main Methods:
- Literature review summarizing existing research on TFPI2's role in various cancers.
- Analysis of structural and microenvironmental factors influencing TFPI2 activity.
- Evaluation of therapeutic potential based on current understanding.
Main Results:
- TFPI2 exhibits context-dependent opposing functions, acting as both a metastasis suppressor and promoter in different cancers (e.g., glioblastoma, melanoma).
- Emerging evidence shows TFPI2 can promote tumor progression by creating an immunosuppressive tumor microenvironment, pathological ECM remodeling, and enhancing angiogenesis and dissemination.
- Divergent expression patterns and context-specific functions are observed within the same metastatic cascade.
Conclusions:
- TFPI2's role in cancer metastasis is complex and highly context-dependent.
- Understanding TFPI2's structural duality and microenvironmental interactions is crucial for its therapeutic application.
- Future research focusing on spatiotemporal microenvironmental dynamics is needed for precise intervention and early screening.
Related Concept Videos
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
The Tumor Microenvironment
